Patients should be monitored closely to ensure that the lowest approved dose of Aranesp is used to provide adequate control of the symptoms of anaemia.
Patsiente peab hoolikalt jälgima, et tagada aneemia adekvaatne sümptomaatiline ravi madalaima kinnitatud Aranesp’ i annusega.